Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1341235/000119312518164070/d576126d10q.htm
Exhibit 99.1
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
LEXINGTON, Mass., May 15, 2018 /PRNewswire/ — Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the first quarter ended March 31, 2018.
“We are pleased with our progress in the first quarter, as we continued to advance our product pipeline for the treatment of immunological diseases,” stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Our research collaboration with Johnson & Johnson Innovation to develop novel drug candidates for systemic inflammatory diseases, the initiation of late-stage clinical testing in dry eye disease and allergic conjunctivitis, and the poster presentations of our ocular inflammation programs, all highlight the promise of our platform across a number of product candidates and indications. We look forward to multiple milestones over the next year, including Phase 2b and Phase 3 clinical results in dry eye disease and allergic conjunctivitis, respectively.”
Recent Highlights
| • | Reproxalap, a novel late-stage product candidate focused on a broad spectrum of inflammatory diseases, continued to progress. |
| • | In January 2018, Aldeyra initiated the enrollment of a Phase 2b clinical trial in patients with dry eye disease (DED). The trial will assess two concentrations of topical reproxalap (0.1% and 0.25%) against vehicle over 12 weeks of treatment in 300 patients with moderate DED. Consistent with Aldeyra’s Phase 2a DED clinical trial, endpoints will include standard signs and symptoms characteristic of the disease. Results from the trial are expected to be announced in the second half of 2018. |
| • | In April 2018, Aldeyra enrolled the first patient in a Phase 3 allergic conjunctivitis clinical trial. The multi-center, double-masked, parallel-group, vehicle-controlled trial is expected to enroll 300 patients, randomized equally to receive either topical ocular 0.25% reproxalap, 0.5% reproxalap, or vehicle in a conjunctival allergen challenge model of acute allergic conjunctivitis. The primary outcome measure will be patient-reported ocular itching. Results from the trial are expected in the second half of 2018, or early 2019. |
| • | Research collaboration initiated with Johnson & Johnson Innovation to advance immune-modulating drugs for systemic inflammatory diseases. In February 2018, Aldeyra entered into an agreement with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to collaborate with Janssen on the development of novel product candidates designed to sequester pro-inflammatory reactive aldehyde species (RASP). The agreement is intended to advance existing analogs of reproxalap for the treatment of systemic inflammatory diseases. |
The following information was filed by Aldeyra Therapeutics, Inc. (ALDX) on Tuesday, May 15, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aldeyra Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aldeyra Therapeutics, Inc..
ALDX Quarterly Reports
- 10-Q Quarterly Report November 2020
- 10-Q Quarterly Report August 2020
- 10-Q Quarterly Report May 2020
- 10-Q Quarterly Report November 2019
- 10-Q Quarterly Report August 2019
- 10-Q Quarterly Report May 2019
- 10-Q Quarterly Report November 2018
- 10-Q Quarterly Report August 2018
-
10-Q Quarterly Report May 2018
- 10-Q Quarterly Report November 2017
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Financial - Expense Highlight
We expect that general and administrative expenses will increase in the future as we expand our operating activities and continue to incur additional costs associated with being a publicly-traded company and maintaining compliance with exchange listing and SEC requirements.
-
Financial - Shares Highlight
If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders.
-
Revenue - Product Highlight
We believe that our cash, cash equivalents, and marketable securities as of March 31, 2018, together with the proceeds of the sales of common stock under the Sales Agreement through May 15, 2018 and the amounts available under the Credit Facility, will be adequate to fund operations into the first quarter of 2020 based on our current business plan.
-
Financial - Expense Highlight
The net proceeds of the offering, including the full exercise of the option, were approximately $10.6 million after deducting underwriting discounts and commissions and the other offering expenses payable by us.
-
Financial - Expense Highlight
The net proceeds of the offering, including the full exercise of the option, were approximately $26.9 million, after deducting underwriting discounts, commissions, and other offering expenses payable by us.
-
Financial - Expense
Pursuant to the Credit Facility,...Read more
-
Other - Other
The Sarbanes-Oxley Act of 2002...Read more
-
Financial - Debt
The issuance of debt could...Read more
-
Financial - Expense
These increases will likely include...Read more
-
Revenue - Product
We have funded our operations...Read more
-
Revenue - Product
We have primarily funded our...Read more
-
Other - Other
The term loans were made...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...
Material Contracts, Statements, Certifications & more
Aldeyra Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Ticker: ALDX
CIK: 1341235
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-18-164070
Submitted to the SEC: Tue May 15 2018 4:05:46 PM EST
Accepted by the SEC: Tue May 15 2018
Period: Saturday, March 31, 2018
Industry: Pharmaceutical Preparations
External Resources:
Insider Transactions
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/aldx/0001193125-18-164070.htm
